Drug resistance, fitness and compensatory mutations in Mycobacterium tuberculosis
Introduction
According to World Health Organization (WHO) [1,2], among the approximately 10 million people who develop tuberculosis each year, about half a million have rifampicin resistant (RIF-R) strains of Mycobacterium tuberculosis (M. tb), 78% of which are also resistant to isoniazid (INH) and termed Multi-Drug-Resistant, or MDR-TB. Of these, about 5–8% have additional resistance to a fluoroquinolone (FQ) and one of the injectable drugs (capreomycin, kanamycin or amikacin), and were termed extensively drug resistant, or XDR-TB. MDR-TB strains only resistant to a FQ are termed pre-XDR-TB. Recently the WHO changed the definition of XDR-TB to indicate resistance to the FQs levofloxacin or moxifloxacin and at least one of the other group I agents – bedaquiline or linezolid [3]. However, as the studies reviewed here were performed before the definition was altered, this review will use the previous definition of XDR-TB. MDR and XDR-TB strains require longer, more expensive treatments than Drug Sensitive (DS) strains, and only about 57% [2,4] of MDR-TB patients who receive treatment are cured, although recently introduced regimens have shown cure rates up to 80% [[5], [6], [7], [8]]. With good reason, drug resistant (DR) strains are seen as a serious impediment to TB control and eradication.
Shortly after Isoniazid (INH) began to be used against tuberculosis (TB) in the 1950s, Middlebrook found that most INH resistant M. tb strains were less virulent in Guinea pigs [[9], [10], [11], [12]], and based largely on these observations, it was believed that DR strains were inherently weaker, or less fit, than DS strains. Because antibiotics generally inhibit enzymes essential for bacterial survival, it is logical that resistance-conferring mutations altering these critical enzymes could result in a loss of fitness: the bacteria grow slower, are transmitted less often and perhaps cause less severe disease [[13], [14], [15], [16], [17]]. However, resistant strains can also acquire secondary, compensatory mutations (CM) that partially or fully restore the fitness cost of the drug resistance conferring mutations. The CM vary depending upon the antibiotic because they mitigate the specific functions compromised by the resistance mutations [18]. Although compensatory mutations are generally more common in strains with resistance mutations incurring the greatest fitness costs, the opposite is true with RIF-R mutations, as described below.
Many MDR and XDR strains are seen in only one or a few patients and may, in fact, be less fit than most DS strains [19], but in regions with high rates of DR-TB, a large part of the MDR burden is often caused by a few dominant, highly transmitted clades of closely related strains [20]. Globally, it is currently estimated that transmission of MDR-TB strains is responsible for over 70% of MDR-TB cases [21]. Is it possible that the differences in strain transmissibility are related to the balance between the fitness costs of the particular mutations conferring resistance and the ability of acquired compensatory mutations to restore the fitness of the resistant strains? To address this question, we review here what is known about the fitness costs of the DR mutations that make a strain MDR or XDR-TB, and the compensatory mutations that fully or partially restore the fitness lost with these DR mutations (Table 1). The studies in this review were largely in vitro, but the putative effects of the DR and CM mutations on the transmission of MDR/XDR-TB outbreak strains are examined in a companion review [22].
Section snippets
Isoniazid
Isoniazid (INH) has been a staple of first-line anti-tuberculosis therapy since shortly after it was discovered (actually rediscovered [23]) in the 1950's. After Middlebrook found that most INH resistant strains appeared to be less virulent in Guinea pigs [[9], [10], [11],24], some TB labs tested for INH resistance by injecting isolates into Guinea pigs, and if the animals survived, the strain was presumed to be INH resistant (INH-R) (personal communication, Instituto Malbran, Buenos Aires,
Rifampicin
When RIF was introduced in the late 1960's and given in combination with isoniazid, it reduced the duration of TB therapy from two years to just 9 months [56]. The target of RIF is the beta subunit of the DNA dependent RNA polymerase (RNAP), the polymerase that synthesizes RNA from the DNA template. Drug resistance mutations alter this critical enzyme and, not surprisingly, incur a fitness cost [[13], [14], [15], [16], [17]]. Several studies have found that 95–98% of all RIF-R M. tb strains
The structural basis of Rif resistance and compensatory mutations
The structure of the DNA dependent RNA Polymerase (RNAP) contains a “crab claw” motif with the upper pincer arm formed by the beta subunit, encoded by rpoB, and the lower by the beta prime (β′) subunit, encoded by rpoC [74]. The RIF binding site is within the beta subunit, close to the site of RNA synthesis on the surface of the deep cleft of the claw, which is the exit tunnel for newly synthesized RNA [75,76]. By binding to RpoB, RIF blocks the elongation of RNA when the transcripts are just
Streptomycin
Studies with Salmonella typhimurium [65] and E. coli [81], found that some mutations conferring streptomycin resistance (STR-R) have a fitness cost and reduced virulence. Although STR is no longer a mainstay of tuberculosis treatment, it is included here because the mechanism to compensate for some STR-R mutations is interesting and novel. Streptomycin interacts with the ribosome to decrease translational accuracy, resulting in mistranslated proteins that are nonfunctional and toxic for the
Other injectable antibiotics
The mutations that confer resistance to the injectable antibiotics – the aminoglycosides kanamycin and amikacin and the tuberactinomycin antibiotics viomycin and capreomycin -- occur mostly in the 16S rRNA, and several different mutations can be selected in vitro. Mutations with the least fitness cost predominate in resistant clinical M. tb strains, particularly the replacement of adenine for guanine at nucleotide 1401(A1401G), which corresponds to 1408 in E. coli [89,90]. Some of the less fit
Gyrase mutations and fluoroquinolone resistance (FQ-R)
There is a suggestion that some pre-XDR and XDR-TB strains are not well transmitted, perhaps due to the FQ-R mutations [20]. Although globally, the FQs are amongst the most widely used antibiotics and FQ-R is a problem in many bacteria [95], there are few reports on the fitness costs of FQ-R mutations. The targets of the FQs are the type II topoisomerases -- DNA gyrase and the Topoisomerase IV (Topo IV), which is similar to the DNA gyrase but not present in mycobacteria. In M. tb, the FQ-R
Author contributions
Amel Kevin Alame Emane: Conceptualization; Formal analysis; Writing original draft
Xujun Guo: Funding acquisition; Supervision; Project administration.
Howard E. Takiff: Conceptualization; Formal analysis; Writing original draft, review & editing.
Shengyuan Liu: Funding acquisition; Supervision; Project administration.
Funding
This work was funded by the Sanming Project of Medicine in Shenzhen (grant number SZSM201603029), and the Institut Pasteur.
Transparency
The authors declare that they have no conflicts of interest and have received no outside influence or remuneration in preparing this review.
Acknowledgments
The authors thank Erik Böttger, Roland Brosch, Iñaki Comas, Francis Drobniewski, Sebastien Gagneux, Qian Gao, Qingyun Liu, João Perdigao, Dick van Soolingen, Catherine Vilcheze and Robin Warren for critically reading earlier versions of the manuscript.
References (109)
- et al.
Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study
Lancet Respir Med
(2017) - et al.
The biological cost of antibiotic resistance
Curr Opin Microbiol
(1999) - et al.
Comparison of fitness of two isolates of Mycobacterium tuberculosis, one of which had developed multi-drug resistance during the course of treatment
J Infect
(2000) Genetics of drug resistance in tuberculosis
Clin Chest Med
(1997)- et al.
Genotypic diversity of multidrug-, quinolone- and extensively drug-resistant Mycobacterium tuberculosis isolates in Thailand
Infect Genet Evol
(2015) - et al.
Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis
Lancet Respir Med
(2015) - et al.
Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update
Tuber Lung Dis
(1998) - et al.
Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria
Clin Microbiol Infect
(2017) - et al.
Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution
Res Microbiol
(2004) - et al.
Crystal structure of Thermus aquaticus core RNA polymerase at 3.3 A resolution
Cell
(1999)
Structural mechanism for rifampicin inhibition of bacterial rna polymerase
Cell
WHO tuberculosis report 2019
WHO tuberculosis report 2020
WHO announces updated definitions of extensively drug-resistant tuberculosis
A trial of a shorter regimen for rifampin-resistant tuberculosis
N Engl J Med
Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis
Am J Respir Crit Care Med
Sustained high rate of successful treatment outcomes: interim results of 75 patients in the Nix-TB clinical study of pretomanid, bedaquiline and linezolid
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis
Lancet Respir Med
Isoniazid susceptibility, catalase activity, and Guinea pig virulence of recently isolated cultures of tubercle bacilli
Am Rev Tubercul
Isoniazid-resistance and catalase activity of tubercle bacilli; a preliminary report
Am Rev Tubercul
Public health significance of tubercle bacilli resistant to isoniazid
Am J Public Health Nation's Health
Tubercle bacilli resistant to isoniazid; virulence and response to treatment with isoniazid in Guinea-pigs
Br Med J
Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli
Science
The molecular mechanisms of drug resistance in Mycobacterium tuberculosis, p 77-114
Comprehensive phenotypic characterization of rifampicin resistance mutations in Salmonella provides insight into the evolution of resistance in Mycobacterium tuberculosis
J Antimicrob Chemother
Evolution and transmission of drug-resistant tuberculosis in a Russian population
Nat Genet
Highly transmitted M. tuberculosis strains are more likely to evolve MDR/XDR and cause outbreaks, but what makes them highly transmitted? Tuberculosis (Edinb)
The story of INH
J Infect Dis
Tubercle bacilli resistant to isoniazid: virulence and response to treatment with isoniazid in Guinea-pigs and mice
Br J Exp Pathol
Characterization of the katG gene encoding a catalase-peroxidase required for the isoniazid susceptibility of Mycobacterium tuberculosis
J Bacteriol
Transformation with katG restores isoniazid-sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations
Mol Microbiol
Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis
Mol Microbiol
The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
Nature
Spontaneous formation of the bioactive form of the tuberculosis drug isoniazid
Angew Chem Int Ed Engl
Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis
J Am Chem Soc
inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis
Science
Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis
Biochemistry
Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis
Mol Microbiol
Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis
Antimicrob Agents Chemother
Understanding molecular consequences of putative drug resistant mutations in Mycobacterium tuberculosis
Sci Rep
Differential sensitivity of mycobacteria to isoniazid is related to differences in KatG-mediated enzymatic activation of the drug
Antimicrob Agents Chemother
A landscape of genomic alterations at the root of a near-untreatable tuberculosis epidemic
BMC Med
Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review
PloS One
Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid
Nat Med
Convergent evolutionary analysis identifies significant mutations in drug resistance targets of Mycobacterium tuberculosis
Antimicrob Agents Chemother
Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis
Science
Emergence of multidrug-resistant Mycobacterium tuberculosis of the Beijing lineage in Portugal and Guinea-Bissau: a snapshot of moving clones by whole-genome sequencing
Emerg Microb Infect
Effects of overexpression of the alkyl hydroperoxide reductase AhpC on the virulence and isoniazid resistance of Mycobacterium tuberculosis
Infect Immun
Role of KatG catalase-peroxidase in mycobacterial pathogenesis: countering the phagocyte oxidative burst
Mol Microbiol
Mycobacterium tuberculosis catalase and peroxidase activities and resistance to oxidative killing in human monocytes in vitro
Infect Immun
Cited by (41)
Novel strategies based on natural products and synthetic derivatives to overcome resistance in Mycobacterium tuberculosis
2024, European Journal of Medicinal ChemistryTuberculosis and diabetes mellitus: Relating immune impact of co-morbidity with challenges in disease management in high burden countries
2022, Journal of Clinical Tuberculosis and Other Mycobacterial DiseasesCitation Excerpt :Achieving optimum glycaemic control is important but can be very difficult due to scarcity of adequate health care facilities, low educational status, and economic disparities in TB patients. A 5-year survey, documenting changes in diabetes practice in developing regions that included 11,799 patients showed that only 20–30 % of patients were at the HbA1c <7 % goal [64]. Poor glycaemic control in Asian populations represents a potentially important risk factor for TB.
- 1
These authors contributed equally to this work.